NeXtGen Biologics

NeXtGen Biologics

Growth Stage

Patented, FDA Cleared, Novel Wound-Care Technology. New Skin In The Game!

Patented, FDA Cleared, Novel Wound-Care Technology. New Skin In The Game!


Raised this Round: Raised: $241,610

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type



Series A

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Alachua, Florida

Business Type

High Growth

NeXtGen Biologics, with a valuation of $40 million, is raising funds on Republic. The company has developed a patented and FDA-cleared wound-care technology involving the extracellular matrix (ECM). The technology captures the regenerative power of the axolotl and has potential applications in general surgery, wounds and burns, plastic surgery, cardiovascular diseases, ophthalmology, and gastrointestinal diseases. The first product of NeXtGen Biologics, NEOMATRIX, is the first ECM product derived from the axolotl and available to physicians and patients. Jonelle Toothman founded NeXtGen Biologics in April 2014. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $5 million. The campaign proceeds will be used for the soft and full-scale launch of NEOMATRIX.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 09/01/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
NeXtGen Biologics on Republic 2022
Platform: Republic
Security Type: SAFE
Valuation: $40,000,000

Follow company

Follow NeXtGen Biologics on Republic 2022

Buy NeXtGen Biologics's Deal Report

Warning: according to the close date for this deal, NeXtGen Biologics may no longer be accepting investments.

NeXtGen Biologics Deal Report

Get KingsCrowd’s comprehensive report on NeXtGen Biologics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NeXtGen Biologics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the NeXtGen Biologics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge